NRx Pharmaceuticals (NRXP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 Nov, 2026Executive summary
Annual meeting scheduled for Dec. 17, 2026, at 10:00 a.m. ET; the Board recommends voting FOR both proposals.
Voting matters and shareholder proposals
Shareholders will vote on Dennis McBride’s election as a director and ratification of Weinberg & Company P.A. as independent auditor for FY 2026.
Board of directors and corporate governance
Dennis McBride is the Board’s nominee for election.
Partial view of Summaries dataset, powered by Quartr API
Latest events from NRx Pharmaceuticals
- Two proposals, a classified Board and detailed related-party oversight shape the 2026 meeting.NRXP
Proxy filing - FDA approval advances preservative-free ketamine toward U.S. launch amid shortages.NRXPFDA announcement
- Preservative-free ketamine and robotic TMS drive innovation, with FDA decision expected soon.NRXP12th Annual Cantor Fitzgerald Global Healthcare Conference
- Monoclonal antibody for ALS enters production, with clinical trials targeted for 2027.NRXPMoody Capital Disruptive Growth & Life Science Conference
- FDA review nearly complete; five million units prepared to address U.S. ketamine shortage.NRXPStatus update
- Regulatory advances, asset acquisition, and $22.3M funding drive growth and clinical expansion.NRXPQ2 2026
- Net loss fell to $1.4M as clinical revenue began and regulatory, clinic, and asset advances accelerated.NRXPQ1 2026
- Advanced drug filings, expanded clinics, improved finances, but funding risks persist.NRXPQ1 2025
- Losses narrowed, NDA filings advanced, and clinic network expansion underway.NRXPQ4 2024